Western blots showed the expression of LC3B on neutrophils treated with platelets from TBI patients, especially those with coagulopathy, and these effects could be decreased with Box A (HMGB1 competitive antagonist) (Figure 3G). Here, MAP1LC3B is linked to blood coagulation disease.